Bristol-Myers Squibb’s stock is up 7% in 2021
Bristol-Myers Squibb Co (NYSE: BMY) is a global biopharmaceutical company focused on the discovery, development and delivery of drugs. The company manufactures prescription drugs and biologics in a variety of therapeutic areas, including cancer, HIV / AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric diseases. Bristol-Myers Squibb also owns 100% of the subsidiaries Celgene and Juno Therapeutics.
Yesterday, June 29th, Bristol-Myers Squibb announced that the European Commission has approved its newest cancer drug Opdivo (nivolumab) plus Yervoy (ipilimumab). The drugs will help adult patients with mismatch repair deficiency or microsatellite instability – high levels of metastatic colorectal cancer – after prior fluoropyrimidine-based combination chemotherapy. In response, BMY was last trading 0.1% at $ 66.37.
Bristol-Myers Squibb stock is up 12% year-over-year and is now up about 11% since it hit its October low of $ 56.75. Additionally, Bristol Myers Squibb stock is up 7% year-to-date, just 2% below its high of $ 67.96 in late May. BMY also has a forward dividend of $ 1.96 and a dividend yield of 2.98%.
In recent history, Bristol-Myers Squibb has a near-squeaky clean reputation in the profit denominations, exceeding Wall Street expectations in all three of its four most recent quarterly earnings reports. It’s worth noting, however, that BMY’s earnings per share (EPS) served as the sole missed result for the most recently reported first quarter of 2021. Analysts are optimistic that earnings will rise in the future, with EPS expected for the current quarter at an estimated $ 1.91.
Bristol-Myers Squibb has seen significant sales growth in recent years. Above all, the company increased sales by 62.6% in the 2020 financial year. In addition, BMY has increased its sales by 104% since the 2017 financial year. However, Bristol-Myers Squibb has suffered massive bottom line losses as the company’s spending has also increased significantly. For fiscal 2020, BMY reported a net loss of $ 9 billion, down $ 12.4 billion from fiscal 2019.
When digging deeper, short-term options traders are optimistic. This corresponds to the security’s put / call open interest ratio (SOIR) of 0.34, which is in the 4th percentile of the year, meaning that calls have rarely been more popular in the past 12 months.
Those looking to get into the next step in Shake Shack stock with options are in luck as rewards are currently available for a bargain price. The security’s Schaeffer’s Volatility Index (SVI) of 16% is in the lower 3rd percentile of last year’s readings, which means that option providers are pricing in low volatility expectations.